Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

2012184 citationsJournal Articlehybrid Open Access

Authors

Carboplatin-PLD led to delayed progression and similar OS compared with carboplatin-paclitaxel in platinum-sensitive ROC.

Good health and well-being

Published in: British Journal of Cancer

Volume 107, Issue 4, pp. 588-591

Field-Weighted Citation Impact: 17.49